About Beyond Gender UK Evidence
The British evidence, dated and sourced
This site records what the United Kingdom has actually decided about youth gender medicine and sex-based rights: the Cass Review, NHS England, the courts, Parliament and the schools guidance, each with a date and a source.
Purpose
Britain produced the most thorough official examination of youth gender medicine anywhere in the world, and then acted on it. That makes the UK record uniquely useful, and uniquely vulnerable to being misquoted. This site sets it out: what the Cass Review found, what NHS England did, what the High Court, Court of Appeal and Supreme Court ruled, what Parliament legislated and what the Department for Education told schools.
How it is organised
Evidence dossiers each cover one question, from puberty blockers to single-sex spaces. Each begins with key facts, sets out the positions and links to primary sources. The UK timeline runs from the first Tavistock referrals data to the present. The sources page collects the judgments, reports and guidance in one place, quoted from the originals wherever possible.
Standards
Facts and dates first. Interpretation is marked as interpretation. Primary sources are preferred to press reports, and where only a press report exists that is stated. Corrections are made when readers supply a link to the original document.
Point of view and publisher
The site is gender-critical. It regards the Cass Review as sound, the reversal on puberty blockers as overdue, and the For Women Scotland judgment as a restatement of what the Equality Act always meant. It is published by Genspect, the international organisation founded in Ireland in 2021, whose founder Stella O'Malley hosts the Beyond Gender podcast with Mia Hughes and Dr Bret Alderman.
Dossiers on the evidence base
The Cass Review: findings and recommendations
The Cass Review was commissioned by NHS England after serious concerns emerged about the capacity, clinical model and evidence base of the national service for children and young people presenting with gender-related distress. For many years, the Tavistock’s Gender Identity Development Service, usually known as GIDS, was the sole national NHS specialist service in England. Referrals rose sharply and the profile of those referred changed substantially, with a marked increase in adolescent girls and young people with complex mental-health, neurodevelopmental and safeguarding needs.
Puberty blockers in the UK: the evidence, the ban and the trial
Puberty blockers are gonadotrophin-releasing hormone analogues, or GnRHa medicines. They suppress the hormonal signals that drive puberty. In paediatric medicine they have established licensed uses, including treatment for central precocious puberty. Their use for children and adolescents experiencing gender incongruence or gender dysphoria is different: it is off-label, meaning that the medicines have not been authorised by the regulator for that indication.